#4574
Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study
Introduction:
Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.
Conference:
Presenting Author:
Hernando Cubero J
Authors:
Rodien-Louw C,
Simo-Servat A,
Dubois M,
Sheppard J,
McDonnell M,
Keywords:
gastroenteropancreatic neuroendocrine tumour,
GEP-NET,
acromegaly,
lanreotide,
LA-SSA,
somatostatin,
patient preference,
#3466
Improving understanding of neuroendocrine tumors (NETs) – A key to improving patient outcomes
Introduction:
The International Neuroendocrine Cancer Alliance (INCA) is a global umbrella organization advocating on behalf of neuroendocrine patients to improve time to diagnosis, care and research.
Conference:
Presenting Author:
McDonnell M
Authors:
McDonnell M,
Kolarova T,
van Genechten D,
Gellerman E,
Dureja S,
Keywords:
neuroendocrine,
awareness,
education,
improve,
outcome,
global,
#3217
Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN) - NET experts & NET healthcare
Introduction:
SCAN assessed global delivery of healthcare to NET patients. This analysis provides a comparative perspective – Advanced Economies (AE) vs. Emerging and Developing Economies (EDE).
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
McDonnell M
Authors:
McDonnell M,
Kolarova T,
Bouvier C,
Pavel M,
Singh H,
Keywords:
access,
NET specialist,
NET healthcare,
challenges,
global,
#2928
Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumour (NET) Patients (SCAN) – Assessment of Early Diagnosis
Introduction:
SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Van Genechten D
Authors:
Van Genechten D,
McDonnell M,
Rodien-Louw C,
Dureja S,
Leyden S,
Keywords:
Neuroendocrine Tumours,
Survey,
Earlier diagnosis,
